Skip to main content

A Revolutionary Approach to Treatment of Complex Diseases

Cellular Nanoparticle Platform Technology

About Cellics Therapeutics

Cellics Therapeutics leverages the multifaceted Cellular Nanoparticle (CNP™) technology to develop nano-therapeutics. Cellics’ dynamic nanoplatform, Cellular Nanosponges, harnesses the power of cell membranes to craft specialized nanoparticle-based therapeutics. Derived from a variety of wild-type or engineered human cells, the CNP™ technology has the potential to address a broad range of diseases. Cellics is a privately held San Diego-based biopharmaceutical company founded by UC San Diego Professor Liangfang Zhang.

Cellular Nanosponge Platform

The Cellular Nanosponge platform includes a supportive nanoparticle core that is coated intact with wild-type or engineered cell membrane. The resulting nanostructure retains the surface protein receptors from the cell membrane, which mirrors innate cells, and can therefore serve as a decoy to bind and neutralize bacterial toxins, cytokines and viruses.

Explore Cellular Nanoparticle Technology

Explore Cellular Nanoparticle Technology

Explore Cellular Nanoparticle Technology

Explore Cellular Nanoparticle Technology

Explore Cellular Nanoparticle Technology

Sign Up for Updates

Sign Up for Updates

Sign Up for Updates

Sign Up for Updates

Sign Up for Updates